Clinical trial · Observational
Anlotinib Therapy in Patients With Advanced Lung Cancer.
Anlotinib Hydrochloride Therapy in Patients With Advanced Lung Cancer: A Real World Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world. Subjects of the study: advanced Lung cancer. Methods of the study: This is a real world, prospective, Non-Interventional, Follow-up registration study. Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle. End point: Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anlotinib Hydrochloride | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- experiment
- description
- The patients whose treatment strategy containing anlotinib.
- interventionNames
- Drug: Anlotinib Hydrochloride
Primary outcomes (1)
- measure
- PFS
- timeFrame
- 1 year
- description
- progression-free survival
Secondary outcomes (3)
- measure
- OS
- timeFrame
- 1 year
- description
- overall survival
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients ≥18 years of age, man or woman, who had to provide written informed consent prior to enrollment. 2. Patients who had to have histologically and/or cytologically confirmed NSCLC that failed at least 2 kinds of systemic chemotherapy (third line or beyond), or who will obtain benefit from antiangiogenic therapy after investigator's assessment. 3. Eastern Cooperative Oncology Group performance status of 0-2. Exclusion Criteria: 1. Contraindication of anlotinib. 2. Pregnant or lactating women. 3. Other patients who can't enroll after investigator's assessment.
References
Publications (0)
Data not yet available